Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431 trial

Patients with myeloid leukemia of Down syndrome (ML-DS) have favorable event-free survival (EFS), but experience significant treatment-related morbidity and mortality. ML-DS blast cells ex vivo have increased sensitivity to cytarabine (araC) and daunorubicin, suggesting that optimizing drug dosing m...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Taub, Jeffrey W., Berman, Jason N., Hitzler, Johann K., Sorrell, April D., Lacayo, Norman J., Mast, Kelley, Head, David, Raimondi, Susana, Hirsch, Betsy, Ge, Yubin, Gerbing, Robert B., Wang, Yi-Cheng, Alonzo, Todd A., Campana, Dario, Coustan-Smith, Elaine, Mathew, Prasad, Gamis, Alan S.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2017
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5482102/
https://ncbi.nlm.nih.gov/pubmed/28389462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-01-764324
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky